DiaMedica Therapeutics Inc. (DMAC) News
Filter DMAC News Items
DMAC News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DMAC News Highlights
- For DMAC, its 30 day story count is now at 2.
- Over the past 7 days, the trend for DMAC's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- HUGE and LEE are the most mentioned tickers in articles about DMAC.
Latest DMAC News From Around the Web
Below are the latest news stories about DIAMEDICA THERAPEUTICS INC that investors may wish to consider to help them evaluate DMAC as an investment opportunity.
Here's Why We're Not Too Worried About DiaMedica Therapeutics' (NASDAQ:DMAC) Cash Burn SituationEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |
Billionaire Lee Cooperman’s 10 Stock Picks with Huge Upside PotentialIn this article, we discuss billionaire Lee Cooperman’s 10 stock picks with huge upside potential. To skip the details of Mr. Cooperman’s life and investment strategy, go directly to Billionaire Lee Cooperman’s 5 Stock Picks with Huge Upside Potential. Leon Cooperman is the true definition of a “self-made” person. He was born in the South […] |
DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call TranscriptDiaMedica Therapeutics Inc. (NASDAQ:DMAC) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Good morning, ladies and gentlemen, and welcome to the DiaMedica Therapeutics Third Quarter 2023 Conference Call. An audio recording of the webcast will be available shortly after the call today on DiaMedica’s website at www.diamedica.com, in the Investor Relations section. Before the […] |
Q3 2023 DiaMedica Therapeutics Inc Earnings CallQ3 2023 DiaMedica Therapeutics Inc Earnings Call |
DiaMedica Therapeutics Inc. (DMAC) Reports Third Quarter 2023 Financial ResultsProtocol Amendments and Increased R&D Spending Mark Q3 2023 |
DiaMedica Therapeutics Insiders Placed Bullish Bets Worth US$20.2mIn the last year, multiple insiders have substantially increased their holdings of DiaMedica Therapeutics Inc... |
DiaMedica Therapeutics Provides a Business Update and Announces Third Quarter 2023 Financial ResultsMINNEAPOLIS, November 13, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for neurological disorders and cardio-renal disease, today provided a business update and financial results for the quarter ended September 30, 2023. Management will host a conference call Tuesday, November 14, 2023, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and third quarter 2023 financial results. |
DiaMedica Therapeutics to Attend the 14th Annual Craig-Hallum Alpha Select Conference November 16, 2023MINNEAPOLIS, November 09, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, today announced that Rick Pauls, its President and CEO and Dave Wambeke, its Chief Business Officer will be participating in the 14th Annual Craig-Hallum Alpha Select Conference being held in New York on Thursday, November 16, 2023. |
DiaMedica Therapeutics to Report Third Quarter 2023 Financial Results and Provide a Business Update November 14, 2023MINNEAPOLIS, November 06, 2023--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company currently focused on developing recombinant KLK1 (DM199) for the treatment of acute ischemic stroke, announced today that its third quarter 2023 financial results will be released after the markets close on Monday, November 13th. DiaMedica will host a live conference call on Tuesday, November 14th at 7:00 AM Central Time to provide a business update and discuss financial results |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on WednesdayPre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning. |